At Turnkey, we use our expertise in innovation and AI to revolutionise life sciences. Our strategic vision involves concepts like reducing the use of animals for toxicity testing and decreasing time to lead discovery. By utilising predictive analytics approaches, we can minimise the reliance on animal testing for toxicity assessment. These approaches enable the extraction of pertinent information, aiding in the discovery of non-invasive biomarkers and facilitating the avoidance or replacement of acute toxicity testing. Additionally, through integrative analysis of multiple profiles, we can extract complementary insights and extrapolate short-term observations to long-term outcomes, thereby reducing the necessity for testing multiple doses and routes of exposure.

Turnkey’s innovative approach aims to decrease the time required for lead discovery by leveraging models that predict target associations in disease models. By utilising DPI, PPI, and PPath networks, we can guide risk assessment and select robust and relevant assays. Cell lines, functional assays, and toxicity assays play a crucial role in this process. With the support of AI and ML, we can accelerate target identification/validation, lead discovery, and selection, ultimately speeding up the overall drug discovery process and reducing failure rates.